| VERICEL CORP. |
| USA |
| Gesundheit |
| US92346J1088 / A12FU4 |
| ATQP (Frankfurt) / VCEL (NASDAQ) |
| FRA:ATQP, ETR:ATQP, ATQP:GR, NASDAQ:VCEL |
| - |
| https://www.vcel.com/ |
|
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutio..
>Volltext.. |
| 1956.3 Mio. EUR |
| 1897.07 Mio. EUR |
| 264.75 Mio. EUR |
| 26.93 Mio. EUR |
| 20.94 Mio. EUR |
| 0.41 EUR |
| 81.74 Mio. EUR |
| 108.35 Mio. EUR |
| 60.22 Mio. EUR |
| 3.09 |
| 26.82% |
| 251.53% |
| - |
| - |
| - |
| VERICEL, AASTROM |
| 15.08.26 |